Literature DB >> 33972508

Pathomechanisms of ALS8: altered autophagy and defective RNA binding protein (RBP) homeostasis due to the VAPB P56S mutation.

Priyanka Tripathi1,2, Haihong Guo1, Joachim Weis1, Anand Goswami3, Alice Dreser1, Alfred Yamoah1,2, Antonio Sechi4, Christopher Marvin Jesse1,5, Istvan Katona1, Panagiotis Doukas1, Stefan Nikolin1, Sabrina Ernst6,7, Eleonora Aronica8, Hannes Glaß9, Andreas Hermann9,10, Harry Steinbusch2,11, Alfred C Feller12, Markus Bergmann13, Dick Jaarsma14.   

Abstract

Mutations in RNA binding proteins (RBPs) and in genes regulating autophagy are frequent causes of familial amyotrophic lateral sclerosis (fALS). The P56S mutation in vesicle-associated membrane protein-associated protein B (VAPB) leads to fALS (ALS8) and spinal muscular atrophy (SMA). While VAPB is primarily involved in the unfolded protein response (UPR), vesicular trafficking and in initial steps of the autophagy pathway, the effect of mutant P56S-VAPB on autophagy regulation in connection with RBP homeostasis has not been explored yet. Examining the muscle biopsy of our index ALS8 patient of European origin revealed globular accumulations of VAPB aggregates co-localised with autophagy markers LC3 and p62 in partially atrophic and atrophic muscle fibres. In line with this skin fibroblasts obtained from the same patient showed accumulation of P56S-VAPB aggregates together with LC3 and p62. Detailed investigations of autophagic flux in cell culture models revealed that P56S-VAPB alters both initial and late steps of the autophagy pathway. Accordingly, electron microscopy complemented with live cell imaging highlighted the impaired fusion of accumulated autophagosomes with lysosomes in cells expressing P56S-VAPB. Consistent with these observations, neuropathological studies of brain and spinal cord of P56S-VAPB transgenic mice revealed signs of neurodegeneration associated with altered protein quality control and defective autophagy. Autophagy and RBP homeostasis are interdependent, as demonstrated by the cytoplasmic mis-localisation of several RBPs including pTDP-43, FUS, Matrin 3 which often sequestered with P56S-VAPB aggregates both in cell culture and in the muscle biopsy of the ALS8 patient. Further confirming the notion that aggregation of the RBPs proceeds through the stress granule (SG) pathway, we found persistent G3BP- and TIAR1-positive SGs in P56S-VAPB expressing cells as well as in the ALS8 patient muscle biopsy. We conclude that P56S-VAPB-ALS8 involves a cohesive pathomechanism of aberrant RBP homeostasis together with dysfunctional autophagy.

Entities:  

Year:  2021        PMID: 33972508     DOI: 10.1038/s41419-021-03710-y

Source DB:  PubMed          Journal:  Cell Death Dis            Impact factor:   8.469


  75 in total

1.  Differential regulation of endoplasmic reticulum structure through VAP-Nir protein interaction.

Authors:  Roy Amarilio; Sreekumar Ramachandran; Helena Sabanay; Sima Lev
Journal:  J Biol Chem       Date:  2004-11-15       Impact factor: 5.157

2.  A common founder for amyotrophic lateral sclerosis type 8 (ALS8) in the Brazilian population.

Authors:  Agnes L Nishimura; Ammar Al-Chalabi; Mayana Zatz
Journal:  Hum Genet       Date:  2005-09-27       Impact factor: 4.132

3.  The p.P56S mutation in the VAPB gene is not due to a single founder: the first European case.

Authors:  A D Funke; M Esser; A Krüttgen; J Weis; M Mitne-Neto; M Lazar; A L Nishimura; A D Sperfeld; P Trillenberg; J Senderek; M Krasnianski; M Zatz; S Zierz; M Deschauer
Journal:  Clin Genet       Date:  2010-03       Impact factor: 4.438

4.  A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis.

Authors:  Agnes L Nishimura; Miguel Mitne-Neto; Helga C A Silva; Antônio Richieri-Costa; Susan Middleton; Duilio Cascio; Fernando Kok; João R M Oliveira; Tom Gillingwater; Jeanette Webb; Paul Skehel; Mayana Zatz
Journal:  Am J Hum Genet       Date:  2004-09-15       Impact factor: 11.025

5.  Coordinated lipid transfer between the endoplasmic reticulum and the Golgi complex requires the VAP proteins and is essential for Golgi-mediated transport.

Authors:  Diego Peretti; Nili Dahan; Eyal Shimoni; Koret Hirschberg; Sima Lev
Journal:  Mol Biol Cell       Date:  2008-07-09       Impact factor: 4.138

Review 6.  The VAP protein family: from cellular functions to motor neuron disease.

Authors:  Sima Lev; Daniel Ben Halevy; Diego Peretti; Nili Dahan
Journal:  Trends Cell Biol       Date:  2008-05-09       Impact factor: 20.808

Review 7.  Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis.

Authors:  Shuo-Chien Ling; Magdalini Polymenidou; Don W Cleveland
Journal:  Neuron       Date:  2013-08-07       Impact factor: 17.173

8.  FFAT rescues VAPA-mediated inhibition of ER-to-Golgi transport and VAPB-mediated ER aggregation.

Authors:  Derek C Prosser; Duvinh Tran; Pierre-Yves Gougeon; Carine Verly; Johnny K Ngsee
Journal:  J Cell Sci       Date:  2008-08-19       Impact factor: 5.285

9.  ERG30, a VAP-33-related protein, functions in protein transport mediated by COPI vesicles.

Authors:  L Soussan; D Burakov; M P Daniels; M Toister-Achituv; A Porat; Y Yarden; Z Elazar
Journal:  J Cell Biol       Date:  1999-07-26       Impact factor: 10.539

Review 10.  mRNP granules. Assembly, function, and connections with disease.

Authors:  J Ross Buchan
Journal:  RNA Biol       Date:  2014       Impact factor: 4.652

View more
  3 in total

Review 1.  VAP Proteins - From Organelle Tethers to Pathogenic Host Interactors and Their Role in Neuronal Disease.

Authors:  Suzan Kors; Joseph L Costello; Michael Schrader
Journal:  Front Cell Dev Biol       Date:  2022-06-08

Review 2.  The Interplay Between Autophagy and RNA Homeostasis: Implications for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.

Authors:  O H Houghton; S Mizielinska; P Gomez-Suaga
Journal:  Front Cell Dev Biol       Date:  2022-04-28

3.  Sequestosome 1 Is Part of the Interaction Network of VAPB.

Authors:  Christina James; Christof Lenz; Henning Urlaub; Ralph H Kehlenbach
Journal:  Int J Mol Sci       Date:  2021-12-09       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.